DF/HCC Program Affiliation

Lung Cancer

Research Abstract

Major Research Focus:

1) Intensity Modulated (IM) Proton vs. IM Photon Radiation Therapy for Lung Cancer:
The maximum tolerated dose (MTD) of intensity modulated (IM) proton and IM photon radiation will be determined in chemo-radiotherapy for medically inoperable stage I and II, and stage III non-small cell lung cancer. This will be followed by a phase III trial to compare IM proton with IM photon at their MTD local tumor control and survival in stage III non-small cell lung cancer.

2) FDG PET Study for Dose-Response Relationship between Residual FDG Uptake 10-12 Days after RT of Chemo-Radiotherapy and Subsequent Tumor Control at 12 months in Inoperable Lung Cancer: To determine residual glucose metabolic rate soon after RT of chemo-radiotherapy which correlates with a 95% probability of tumor control. This value is a very useful biomarker for guiding radiation therapy for the optimum outcome. For this study, over 100 patients have been enrolled.

3) FDG PET Imaging in Esophageal Cancer:
To correlate 18F-FDG uptake and tumor response in preoperative chemoradiotherapy and surgery.

4) Study of Neoadjuvant Chemo-Radiotherapy for Stage IIIA (N2) Non-Small Cell Lung Cancer:
To search for a radiation dose schedule higher than the conventional dose schedule of 45 Gy/25 F/5 weeks for better tumor downsizing, higher complete resection rate and improved 5-year survival rate in preoperative chemo-radiotherapy for marginally resectable stage IIIA (N2) non-small cell lung cancer. This is a phase I/II study in which the maximum tolerated dose (MTD) of radiation will be determined by a dose escalation schedule using a hybrid QD (to the initial target volume) and BID (to the gross target volume) radiation synchronized with chemotherapy cycles (cisplatin, 5-FU and Taxol). In phase II part of this study, the MTD of radiation will be tested for toxicities, tumor downstaging and survival.

Publications

• Choi NC, Herndon JE, Rosenman J, Carey RW, Chung CT, Bernard S, Leone L, Seagren S, Green M.Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurr
  9817271